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OBJECTIVE — To validate continuous glucose monitoring (CGM) in children and adoles-
cents with cystic ﬁbrosis.
RESEARCH DESIGN AND METHODS — Paired oral glucose tolerance tests (OGTTs)
and CGM monitoring was undertaken in 102 children and adolescents with cystic ﬁbrosis (age
9.5–19.0years)atbaseline(CGM1)andafter12months(CGM2).CGMvaliditywasassessedby
reliability, reproducibility, and repeatability.
RESULTS — CGM was reliable with a Bland-Altman agreement between CGM and OGTT of
0.81 mmol/l (95% CI for bias  2.90 mmol/l) and good correlation between the two (r 
0.74–0.9; P  0.01). CGM was reproducible with no signiﬁcant differences in the coefﬁcient of
variation of the CGM assessment between visits and repeatable with a mean difference between
CGM1 and CGM2 of 0.09 mmol/l (95% CI for difference  0.46 mmol/l) and a discriminant
ratio of 13.0 and 15.1, respectively.
CONCLUSIONS — In this cohort of children and adolescents with cystic ﬁbrosis, CGM
performed on two occasions over a 12-month period was reliable, reproducible, and repeatable.
Diabetes Care 32:1020–1022, 2009
L
ittle is known about the evolution of
diabetes and pancreatic disorders in
adults with cystic ﬁbrosis (CF) and
less in children and adolescents with cys-
tic ﬁbrosis. Patients with CF-related dia-
betes have a sixfold increase in morbidity
and mortality (1). The diagnosis of CF-
related diabetes is usually asymptomatic,
lying dormant for 2–6 years before diag-
nosis (1–3). Identiﬁcation of disordered
glucose metabolism before major -cell
loss may be beneﬁcial, since early insulin
therapy improves lung function and re-
duces the number of acute respiratory in-
fections (4,5).
Standardmethodsofglycemicassess-
ment, random or fasting glucose concen-
trations, and/or oral glucose tolerance
tests (OGTTs) underdiagnose CF-related
diabetes (6). Continuous glucose moni-
toring (CGM) in the normal glucose tol-
erance (NGT) and impaired glucose
tolerance (IGT) stages may allow earlier
diagnosis of CF-related diabetes (7), but
beforethismethodologycanbeappliedto
children and adolescents with CF, valida-
tion is required. Consequently, we have
assessed CGM in terms of reliability, re-
peatability, and reproducibility in 102
children and adolescents with CF on two
occasions over 24 months.
RESEARCH DESIGN AND
METHODS— A prospective multi-
center cohort study of 102 genetically
conﬁrmed children and adolescents with
CF (48 males, 54 females) aged 9.5–19.0
years was conducted over 24 months. All
childrenunderwent“pairedtesting,”with
OGTT and CGM and the initial OGTT
used to classify children and adolescents
with CF into three groups: NGT, IGT,
or CF-related diabetes based on World
Health Organization criteria (8). CGM
(Medtronic Minimed CGM Gold; Med-
tronic Diabetes, Watford, U.K.) was re-
corded at the start of the study (CGM1
visit1)andafteraminimumof12months
(CGM2 visit 2). Blood glucose concentra-
tionwasmeasuredusingaYSIcompatible
CX7 Delta Analyzer. After the OGTT was
complete, the CGM device remained in
situ in the home environment for 72 h on
all patients. Patients entered a minimum
offourself-monitoredbloodglucosesam-
ples (One Touch Ultra meter; LifeScan,
Milpitas, CA) for daily CGM calibration.
Ethical approval was obtained from the
ethics committees of the three participat-
ing hospitals. The study protocol was
carried out in accordance with the Decla-
ration of Helsinki.
Statistical analysis
All data were extracted from the
Medtronic Mini Med Solutions CGM sen-
sor, MMT-730 version 3.0c (3.0.128).
Mean and SD of the interstitial glucose
concentrations for all CGM recordings
were derived. Analysis was performed in
SPSS version 15.
Validity of CGM in children and ado-
lescentswithCFwasassessedbydetermi-
nation of reliability, reproducibility, and
repeatability. Reliability was assessed by
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(9,10) along with Pearson’s correlation
coefﬁcient. Reproducibility tested the
null hypothesis that the mean difference
between the coefﬁcients of variation
(CVs) of observations was zero using a
paired Student’s t test. Repeatability was
derived from Bland-Altman analysis and
calculation of a discriminant ratio (DR)
(11). Data are expressed as mean values
with 95% CIs where appropriate. Signiﬁ-
cance was set at the 5% level.
RESULTS— A total of 104 out of 160
children and adolescents with CF (aged
9.5–19.0years)werestudied.Atotalof102
valid CGM results were obtained at CGM1
and 92 at CGM2. The average number of
valid CGM sensor readings used was 710
(range 499–1,410).
Mean interstitial CGM glucose for all
children and adolescents with CF was
6.7  2.3 mmol/l (means  SD) on
CGM1 and 7.0  2.6 mmol/l CGM2.
Mean interstitial CGM glucose for NGT,
IGT, and CF-related diabetes is shown in
Table 1. All values were signiﬁcantly
higher than in normal healthy nondia-
betic subjects (mean 5.1  0.7 mmol/l,
P  0.0001).
Validitation of CGM in CF
Reliability. Bland and Altman analysis
revealed a mean difference between CGM
glucose and OGTT glucose of 0.81 
1.47 mmol/l with a 95% CI of the bias 
2.90mmol/l.Asigniﬁcantcorrelationwas
found between glucose measured by
CGM and the blood glucose at ﬁve time
points in a standard OGTT (r  0.74–
0.91, P  0.01).
Reproducibility. Reproducibility was
assessed by comparing CVs at ﬁve differ-
ent time points of OGTT and within the
subgroups (Table 1). There were no sig-
niﬁcantdifferencesintheCVsoftheCGM
assessment between visits, irrespective of
glucose tolerance category.
Repeatability. The mean difference be-
tween CGM1 and CGM2 interstitial glu-
cose concentrations was 0.09  2.38
mmol/l with 95% CI for the difference
of  0.46 mmol/l. The DRs (the variabil-
ityofanindividualtothevariabilityofthe
group) for CGM1 and CGM2 were 13.0
and 15.1, respectively. Subgroup DRs are
shown in Table 1 and indicate that CGM
has the ability to identify subjects with
highvariability,suchasCF-relateddiabe-
tes, within this cohort of children and ad-
olescents with CF.
CONCLUSIONS— This study dem-
onstrates that CGM is a valid method for
assessing glycemia in children and adoles-
cents with CF, extending similar observa-
tions in adults with CF (7). The validation
of CGM in children and adolescents
with CF is essential before other pro-
spective research can be undertaken
with CGM in children and adolescents
with cystic ﬁbrosis and is warranted
because of the higher glucose concen-
trations observed in these patients com-
pared with the general population.
As expected, there was a linear corre-
lation between ﬁve-point OGTT plasma
blood glucose and the corresponding
CGM glucose readings (r  0.74–0.91).
Rather than use correlation or Clarke er-
ror grid analysis, which both describe as-
sociation, we used Bland-Altman analysis
of agreement (9,10). The mean difference
between the two methods was 0.81
mmol/l with a 95% CI  2.90 mmol/l,
which is a reasonably acceptable bias for
clinical practice.
CGM was reproducible in children
with CF with varying degrees of glucose
intolerance, since there were no signiﬁ-
cant differences in the CVs of the CGM
assessment between visits, irrespective of
diagnosis.
Finally, we have demonstrated that
CGM was repeatable as the mean differ-
ence between CGM1, and CGM2 was
0.09 mmol/l. Further, all DRs were 1,
indicatingthatCGMhastheabilitytodis-
criminate between different subjects and
allow comparison between subjects.
In conclusion, CGM is a valid mea-
sure of glycemia in children and adoles-
centswithCF.Theseobservationssuggest
that CGM is not inﬂuenced by the CF
chloride channel defect and has become a
useful tool for the assessment of glycemia
in children and adolescents with CF.
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